The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Vanita Aroda is the Director of Diabetes Clinical Research at the Brigham and Women's Hospital in Boston, MA, and is Member of the Faculty of Harvard Medical School. Dr. Aroda completed her training in Internal Medicine and in Endocrinology, Diabetes and Metabolism at the University of California San Diego, CA, USA.
Dr. Aroda has an interest and published record in diabetes prevention and novel therapeutics in diabetes and weight management. She also has a strong interest in understanding therapeutic interventions in large multicenter clinical trials and their applicability and integration into care. Dr. Aroda has years of experience in clinical trial conduct and leadership, has served as an investigator on the National Institutes of Health-funded GRADE, D2d, and DPPOS studies, and as the national or international signatory Principal Investigator for multiple therapeutic clinical trials. Dr. Aroda serves on the Professional Practice Committee of the American Diabetes Association.
Filip Krag Knop
University of Copenhagen, Copenhagen, Denmark
Filip K. Knop, MD PhD, is a professor of endocrinology and director of Center for Clinical Metabolic Research at Gentofte Hospital, University of Copenhagen, and consultant endocrinologist at Steno Diabetes Center Copenhagen. Prof. Knop has been involved in diabetes and metabolic research since his fellowship at The Distinguished Gifford Laboratories for Diabetes Research, University of Texas, Southwestern Medical Center in Dallas in 1999 (supervised by Christopher B. Newgard). Knop received his MD degree in 2002 and his PhD in medical sciences in 2007 from University of Copenhagen (supervisor: Jens J. Holst). Knop’s research centres on human metabolism, the pathophysiology of obesity and related disorders including type 2 diabetes and non-alcoholic fatty liver disease, regulation of appetite and food intake, and the therapeutic potential of factors involved in these processes. The Knop laboratory has reported several novel findings describing the integrative role of the gut and the liver in human (patho)physiology.
Prof. Knop has authored 378 peer-reviewed scientific publications and he has received several honours for his research (e.g. named “Rising star” by the European Association for the Study of Diabetes (EASD) in 2010, the DPLU/LUDC Nordic Prize for an Outstanding Young Diabetes Investigator (2011), Johan Quentin and Wife’s Prize for Outstanding Research (2014), The Capital Region of Denmark’s Global Excellence Prize (2014), The Thomsen Prize (2015), The Niels Schwartz Sørensen Prize (2017), The Danish Odd Fellowship’s Research Prize (2017), the European Journal of Endocrinology Prize 2018, and EASD’s Minkowski Prize 2019). He serves as a referee for several international journals including The Lancet, British Medical Journal, Diabetes and Diabetologia and he is a member of numerous professional societies and committees.